
|Slideshows|May 3, 2016
Clinical Trial Highlights: AAN 2016 – Part 1
Author(s)Samantha J. Peterson
From no evidence of disease activity in MS to studies of a new treatment for periodic paralysis, AAN 2016 featured many exciting clinical trials.
Advertisement
Some of the best new research developments were highlighted at the Clinical Trials plenary session on April 20 during AAN 2016. In part 1 of this slideshow, we share results of the first four of eight trials featured. Natalia S. Rost, MD, Vice Chair of the Science Committee and Petra Kauffman, MS, member of the Science Committee, led the session.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Anti-IL6R Therapy Effective in Reducing NMOSD and MOGAD Disease Activity
2
VMAT2 Inhibitor NBI-1065890 Heads to Phase 2 Study in Tardive Dyskinesia
3
Phase 3 EMBARK Data Released, CTE Associated with Dementia Risk, Pilavapadin Heads to Phase 3 Pain Studies
4
NeurologyLive® Brain Games: February 1, 2025
5









